Evaluating a Novel Human Fibrinogen Concentrate (BT524) for Congenital Fibrinogen Deficiency
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”Excited to share our new publication evaluating a novel human fibrinogen concentrate (BT524) for the treatment of congenital fibrinogen deficiency!
This fibrinogen concentrate includes three independent virus inactivation and removal steps to ensure maximum viral safety.
In this prospective Phase I/III trial, BT524 was investigated in 27 patients (15 adults and 12 children) with congenital afibrinogenemia or severe hypofibrinogenemia:
- Single-dose administration (70 mg/kg) effectively increased fibrinogen antigen levels from undetectable to therapeutic levels
- Half-life: 67.9 hours (FiAg) and 60.3 hours (FiAc) – providing sustained hemostatic coverage
- Significant improvement in clot firmness (FIBTEM MCF +11.1 mm, p < 0.0001) within 1 hour
- Excellent safety profile – only one mild treatment-related adverse event (increased D-dimer), with no thromboembolic events, hypersensitivity reactions, or inhibitor development.
This new fibrinogen concentrate demonstrates excellent pharmacokinetics while providing an outstanding safety and tolerability profile across all age groups.
An important step forward for patients with this ultra-rare bleeding disorder, and a important improvement in the evolution of fibrinogen replacement therapy.
Congratulations to the study team, the co-authors and Biotest— more exciting work ahead!”
Read the full article here.
Article: Pharmacokinetics, Hemostatic Efficacy, and Safety of a New Human Fibrinogen Concentrate in Adult and Pediatric Patients with Congenital Fibrinogen Deficiency
Authors: Claudia Djambas Khayat, Amal El-Beshlawy, Balkis Meddeb, Abderrahim Khelif, Wolfgang Miesbach, Sonia Adolf, Heike Boehm, Silke Aigner, Salomon Abraha , Fabian Bohlaender, Joerg Schuettrumpf

Stay updated on all scientific advances Hemostasis Today.
-
Aug 12, 2026, 08:16Chengyong Yang: Can Plasma Reveal Cell Specific Signals
-
Aug 12, 2026, 07:49Alan Dursun: Phnom Penh, Cambodia – Part 3 – Turning Partnership into Action
-
Aug 12, 2026, 06:55Alejandro González Veliz: A Good PCI is not Just about Opening the Artery
-
Aug 12, 2026, 06:39Abdulmalik Alnuqydan: Why Do We Transfuse RBCs Less Than 7 Days Old to Newborns?
-
Aug 12, 2026, 06:24Lucas Jae: How Mitochondria Sense Heme Scarcity to Regulate Heme and Globin Production
-
Aug 12, 2026, 06:09Luis Tam։ New CDC Global Health Security Funding Opportunities
-
Aug 12, 2026, 06:09Yan Leyfman: Curative Strategies and Precision Medicine in Sickle Cell Disease
-
Aug 12, 2026, 06:01Sophie He: Exploring Manufacturing Scalability and Cell Separation
-
Aug 12, 2026, 05:54Yuan Goessi: One Bleed Is One Too Many for a Lifetime of Haemophilia A